The Impact of Including Costs and Outcomes of Dementia in a Health Economic Model to Evaluate Lifestyle Interventions to Prevent Diabetes and Cardiovascular Disease

Penny Breeze, Chloe Thomas, Praveen Thokala, Louise Lafortune, Carol Brayne and Alan Brennan
Additional contact information
Penny Breeze: School of Health and Related Research, University of Sheffield, Sheffield, South Yorkshire, UK
Chloe Thomas: School of Health and Related Research, University of Sheffield, Sheffield, South Yorkshire, UK
Praveen Thokala: School of Health and Related Research, University of Sheffield, Sheffield, South Yorkshire, UK
Louise Lafortune: Cambridge Institute of Public Health, University of Cambridge, Cambridge, Cambridgeshire, UK
Carol Brayne: Cambridge Institute of Public Health, University of Cambridge, Cambridge, Cambridgeshire, UK
Alan Brennan: School of Health and Related Research, University of Sheffield, Sheffield, South Yorkshire, UK

Medical Decision Making, 2020, vol. 40, issue 7, 912-923

Abstract: Objectives Economic evaluations of lifestyle interventions, which aim to prevent diabetes/cardiovascular disease (CVD), have not included dementia. Lifestyle interventions decrease dementia risk and extend life expectancy, leading to competing effects on health care costs. We aim to demonstrate the feasibility of including dementia in a public health cost-effectiveness analysis and quantify the overall impacts accounting for these competing effects. Methods The School for Public Health Research (SPHR) diabetes prevention model describes individuals’ risk of type 2 diabetes, microvascular outcomes, CVD, congestive heart failure, cancer, osteoarthritis, depression, and mortality in England. In version 3.1, we adapted the model to include dementia using published data from primary care databases, health surveys, and trials of dementia to describe dementia incidence, diagnosis, and disease progression. We estimate the impact of dementia on lifetime costs and quality-adjusted life years (QALYs) gained of the National Health Service diabetes prevention program (NHS DPP) from an NHS/personal social services perspective with 3 scenarios: 1) no dementia, 2) dementia only, and 3) reduced dementia risk. Subgroup, parameter, and probabilistic sensitivity analyses were conducted. Results The lifetime cost savings of the NHS DPP per patient were £145 in the no-dementia scenario, £121 in the dementia-only scenario, and £167 in the reduced dementia risk scenario. The QALY gains increased by 0.0006 in dementia only and 0.0134 in reduced dementia risk. Dementia did not alter the recommendation that the NHS/DPP is cost-effective. Conclusions Including dementia into a model of lifestyle interventions was feasible but did not change policy recommendations or modify health economic outcomes. The impact on health economic outcomes was largest where a direct impact on dementia incidence was assumed, particularly in elderly populations.

Keywords: cost-effectiveness analysis; dementia; non-communicable disease; public health; simulation (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X20946758 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:40:y:2020:i:7:p:912-923

DOI: 10.1177/0272989X20946758

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().